Spots Global Cancer Trial Database for Clinical Study of Liposomal Paclitaxel in Chinese Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical Study of Liposomal Paclitaxel in Chinese Patients
Official Title: Dose Escalation Study of Liposomal Paclitaxel in Chinese Patients With Advanced Solid Tumors
Study ID: NCT00881101
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the maximum tolerated dose and dose limiting toxicities of liposomal paclitaxel in Chinese patients with solid tumors in advanced stages.
Detailed Description: There are clinical trials show that paclitaxel is common option for the treatment of solid tumors. Liposomal paclitaxel has different pharmacokinetic features comparing with conventional paclitaxel. However,the tolerance of this new dosage form of paclitaxel (liposomal paclitaxel) has never been studied in Chinese cancer patients. This study is designed to find the maximum tolerated dose and dose limiting toxicities of liposomal paclitaxel in Chinese cancer patients.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The ethics committee of Cancer Hospital of Fudan University, Shanghai, Shanghai, China
Contact Details
Name: Jin Li, Dr.
Affiliation: Cancer Hospital of Fudan University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
